Treatment of experimental brain metastasis with MTO-liposomes: Impact of fluidity and LRP-targeting on the therapeutic result

Pharmaceutical Research

Volumn 29, Issue 7, 2012, Pages 1949-1959

  Orthmann, Andrea ^a   Zeisig, Reiner ^b   Süss, Regine ^c   Lorenz, Dorothea ^d   Lemm, Margit ^a   Fichtner, Iduna ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Experimental Pharmacology and Oncology Berlin Buch GmbH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

brain metastases; LRP; targeting; transcytosis; uptake

Indexed keywords

LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TARGETING; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; TRANSCYTOSIS; TRANSPORT VESICLE; TREATMENT OUTCOME; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LIPOSOMES; MICE; MITOXANTRONE; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84862617442     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0723-7     Document Type: Article

References (44)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
2. Pardridge WM. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc. 2010;(4) (2010), db.
3. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des. 2009;15(8):917-25.
4. Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M. Lipid nanoparticles for drug delivery to the brain: in vivo veritas. J Biomed Nanotechnol. 2009;5(4):344-50.
5. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
6. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv. 2006;3(2):219-32.
7. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target. 2010;18(3):157-67.
8. Orthmann A, Zeisig R, Koklic T, Sentjurc M, Wiesner B, Lemm M, et al. Impact of membrane properties on uptake and transcytosis ofcolloidal nanocarriers across an epithelial cell barrier model. J Pharm Sci. 2010;99(5):2423-33.
9. Chamberlain MC. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev Neurother. 2010;10(4):547-61.
10. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009;6(10):1017-32.
11. Orthmann A, Fichtner I, Zeisig R. Improving the transport of chemotherapeutic drugs across the blood-brain barrier. Expert Rev Clin Pharmacol. 2011;4(4):465-78.
12. Cerletti A, Drewe J, Fricker G, Eberle AN, Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target. 2000;8(6):435-46.
13. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res. 2007;24(9):1772-87.
14. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials. 2009;30(23-24):3986-95.
15. Feng B, Tomizawa K, Michiue H, Miyatake S, Han XJ, Fujimura A, et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials. 2009;30(9):1746-55.
16. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008;106 (4):1534-44.
17. Li Y, Cam J, Bu G. Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol Neurobiol. 2001;23(1):53-67.
18. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887-918.
19. Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr. 1999;19:141-72.
20. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau R. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324(3):1064-72.
21. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185-97.
22. Che C, Yang G, Thiot C, Lacoste MC, Currie JC, Demeule M, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem. 2010;53(7):2814-24.
23. Chan WC, White PD. Fmoc solid phase peptide synthesis - A practical Approach. Oxford: Oxford University Press; 2000.
24. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758(10):1633-40.
25. Gantert M, Lewrick F, Adrian JE, Rossler J, Steenpass T, Schubert R, et al. Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharm Res. 2009;26(3):529-38.
26. Zeisig R, Müller K, Maurer N, Arndt D, Fahr A. The composition-dependent presence of free (micellar) alkylphospholipid in liposomal formulations of octadecyl-1,1-dimethyl-piperidino-4-yl-phosphate affects its cytotoxic activity in vitro. J Membr Biol. 2001;182(1):61-9.
27. Naundorf H, Fichtner I, Saul GJ, Haensch W, BÜttner B. Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. J Cancer Res Clin Oncol. 1993;119(11):652-6.
28. Johnson JL, Ahmad A, Khan S, Wang YF, Abu-Qare AW, Ayoub JE, et al. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799(1):149-55.
29. Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21(1):15-23.
30. Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging. 2011;32(12):2323e1-11.
31. Gubernator J, Chwastek G, Korycinska M, Stasiuk M, Grynkiewicz G, Lewrick F, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release. 2010;146(1):68-75.
32. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm. 2008;68(3):607-17.
33. Zucker D, Barenholz Y. Optimization of vincristine-topotecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release. 2010;146(3):326-33.
34. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2):197-224.
35. Zeisig R, Eue I, Kosch M, Fichtner I, Arndt D. Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation. Biochim Biophys Acta. 1996;1283(2):177-84.
36. Xi X, Yang F, Chen D, Luo Y, Zhang D, Gu N, et al. A targeting drug-delivery model via interactions among cells and liposomes under ultrasonic excitation. Phys Med Biol. 2008;53(12):3251-65.
37. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343-75.
38. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, Borm P, Estrada G, Ntziachristos V, Razansky D. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010;7(3):3. doi:10.1186/1743-8977-7-3.
39. Yemisci M, Bozdag S, Cetin M, Soylemezoglu F, Capan Y, Dalkara T, et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery. 2006;59(6):1296-302.
40. Boiardi A, Eoli M, Salmaggi A, Lamperti E, Botturi A, Broggi G, et al. Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol. 2005;75(2):215-20.
41. Boiardi A, Eoli M, Salmaggi A, Lamperti E, Botturi A, Solari A, et al. Local drug delivery in recurrent malignant gliomas. Neurol Sci. 26 2005; Suppl 1(S37-9):S37-S39.
42. Kawano K, Onose E, Hattori Y, Maitani Y. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone. Mol Pharm. 2009;6(1):98-104.
43. van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release. 2011;150(1):30-6.
44. Zeisig R, Koklic T, Wiesner B, Fichtner I, Sentjurc M. Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys. 2007;459(1):98-106.